Today, more than 75 percent of pharmaceutical drug trials in the United States are being conducted in the private sector. Once the sole province of academic researchers, these important studies are now being outsourced to non-academic physicians. According to Jill A. Fisher, this major change in the way medical research is performed is the outcome of two problems in U.S. health care: decreasing revenue for physicians and decreasing access to treatment for patients. As physicians report diminishing income due to restrictive relationships with insurers, increasing malpractice insurance premiums, and inflated overhead costs to operate private practices, they are attracted to pharmaceutical contract research for its lucrative return. Clinical trials also provide limited medical access to individuals who have no or inadequate health insurance because they offer "free" doctors' visits, diagnostic tests, and medications to participants. Focusing on the professional roles of those involved, as well as key research practices, Fisher assesses the risks and advantages for physicians and patients alike when pharmaceutical drug studies are used as an alternative to standard medical care. A volume in the Critical Issues in Health and Medicine series, edited by Rima D. Apple and Janet Golden
This book is open access under a CC-BY license. The importance of the pharmaceutical industry in Sub-Saharan Africa, its claim to policy priority, is rooted in the vast unmet health needs of the sub-continent. Making Medicines in Africa is a collective endeavour, by a group of contributors with a strong African and more broadly Southern presence, to find ways to link technological development, investment and industrial growth in pharmaceuticals to improve access to essential good quality medicines, as part of moving towards universal access to competent health care in Africa. The authors aim to shift the emphasis in international debate and initiatives towards sustained Africa-based and African-led initiatives to tackle this huge challenge. Without the technological, industrial, intellectual, organisational and research-related capabilities associated with competent pharmaceutical production, and without policies that pull the industrial sectors towards serving local health needs, the African sub-continent cannot generate the resources to tackle its populations' needs and demands. Research for this book has been selected as one of the 20 best examples of the impact of UK research on development. See http://www.ukcds.org.uk/the-global-impact-of-uk-research for further details.
With debates surrounding the decriminalisation of certain illegal drugs raging in many countries around the world, this new book is a timely and sober reflection on one of the biggest social problems facing the world at large. Of interest not only to economists, but also to criminologists and those involved in policy-making, The Economics of Illega
This book offers systematic comparative analysis of the political economy of pharmaceutical patents in Latin America, and examines the diverse ways that international changes can reconfigure domestic politics.
'This impressive collection offers fascinating new perspectives on the impact of pharmaceutical patents on access to medicines in developing countries. The volume's editors have put together an important book that sets out clearly the challenges to public health in a wide range of national contexts. The book will be a valuable text for all scholars and decision-makers interested in the global politics of intellectual property rights and public health.' – Duncan Matthews, Queen Mary, University of London, UK This up-to-date book examines pharmaceutical development, access to medicines, and the protection of public health in the context of two fundamental changes that the global political economy has undergone since the 1970s, the globalization of trade and production and the increased harmonization of national regulations on intellectual property rights. With authors from eleven different countries presenting case studies of national experiences in Africa, Asia and the Americas, the book analyzes national strategies to promote pharmaceutical innovation, while at the same time assuring widespread access to medicines through generic pharmaceutical production and generic pharmaceutical importation. The expert chapters focus on patents as well as an array of regulatory instruments, including pricing and drug registration policies. Presenting in-depth analysis and original empirical research, this book will strongly appeal to academics and students of intellectual property, international health, international political economy, international development and law.
Drugs, Crime and Public Health provides an accessible but critical discussion of recent policy on illicit drugs. Using a comparative approach - centred on the UK, but with insights and complementary data gathered from the USA and other countries - it argues that problematic drug use can only be understood in the social context in which it takes place.
Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. This volume is the first cross-country analysis of how TRIPS has affected the capacity of 11 major low or medium income countries to produce generic drugs.
This scholarly examination of the worldwide web of narcotics today provides students, social workers, health providers, law enforcement officers and policy makers with an up-to-date, overall exploration of the world of drugs. Vast resources are pumped into the 'war on drugs'. But in practice, prohibition has failed. Narcotics use continues to rise, while technology and globalisation have made a whole new range of drugs available to a vast consumer market. Where wealth and demand exist, supply continues to follow. Prohibition has failed to stem consumption and production, criminalised social groups, impeded research into alternative medicine and disease, promoted violence and gang warfare, and impacted negatively on the environment. The alternative is a humane policy framework that recognizes the incentives to produce, traffic and consume narcotics.
"This comprehensive volume makes a substantive and unique contribution to understanding the drug trade at the national, regional, and global levels. Bringing together respected scholars and analysts from diverse disciplines and from Latin America, Europe, and the United States, it is the most important single volume in the field this decade."--Michael Gold-Biss, American University Stemming from an international conference held in Utrecht, this collection encompasses the political, economic, social, and legal aspects of the illegal drug industry. The introduction provides an overview of the political economy of the drug industry followed by discussions of the impact of the drug industry on the Latin American source countries; drug trafficking and money laundering; the war on drugs, transnational crime, and international security; and current options for intervention and control. Contents Part I. Introduction 1. The Political Economy of the Drug Industry: Its Structure and Functioning, by Menno Vellinga Part II. The Drug Industry: Its Impact on Economy, Politics, and Society and the Drug Control Effort in Source Countries 2. Has Bolivia Won the War? Lessons from Plan Dignidad, by Eduardo A. Gamarra 3. Questionable Alliances in the War on Drugs: Peru and the United States, by Mariano Valderrama and Hugo Cabieses 4. Illegal Drugs in Colombia: From Illegal Economic Boom to Social Crisis, by Francisco E. Thoumi 5. Mexico: Drugs and Politics, by Luis Astorga 6. The Political Economy of Drugs in the Caribbean: Problems without Passports, by Ivelaw L. Griffith Part III. Trafficking and Money Laundering 7. The Political Economy of Drug Smuggling, by Peter Reuter 8. Post-Fordist Cocaine: Labor and Business Relations among Colombian Dealers, by Damián Zaitch 9. Follow the Money: Anti-Money-Laundering Policies and Financial Investigations, by Ernesto Savona Part IV. The Drug Industry and the War on Drugs 10. Perversely Harmful Effects of Counter-Narcotics Policy in the Andes, by Rensselaer Lee 11. Diverging Trends in Global Drug Policy, by Martin Jelsma 12. Multilateral Drug Control, by Sandeep Chawla 13. The European Union and Drug Control: Issues and Trends, by Tim Boekhout van Solinge Part V. Drugs, Transnational Crime, and International Security 14. Globalization and Transnational Organized Crime: The Russian Mafia in Latin America and the Caribbean, by Bruce Michael Bagley 15. The War against Drugs and the Interests of Governments, by Alain Labrousse 16. Drugs and Transnational Organized Crime: Conceptualization and Solutions, by Ybo Buruma Part VI. Conclusion 17. The Drug Industry, Its Economic, Social, and Political Effects, and the Options of Intervention and Control, by Menno Vellinga Menno Vellinga has served as professor of development geography and director of the Institute of Development Studies at Utrecht University, the Netherlands. He presently occupies the Bacardi Chair for Eminent Visiting Scholars at the Center for Latin American Studies at the University of Florida.
Continuing his pioneering theoretical explorations into the relationships among biosciences, the market, and political economy, Kaushik Sunder Rajan introduces the concept of pharmocracy to explain the structure and operation of the global hegemony of the multinational pharmaceutical industry. He reveals pharmocracy's logic in two case studies from contemporary India: the controversial introduction of an HPV vaccine in 2010, and the Indian Patent Office's denial of a patent for an anticancer drug in 2006 and ensuing legal battles. In each instance health was appropriated by capital and transformed from an embodied state of well-being into an abstract category made subject to capital's interests. These cases demonstrate the precarious situation in which pharmocracy places democracy, as India's accommodation of global pharmaceutical regulatory frameworks pits the interests of its citizens against those of international capital. Sunder Rajan's insights into this dynamic make clear the high stakes of pharmocracy's intersection with health, politics, and democracy.
